Author:
Minderman Hans,O’Loughlin Kieran L.,Smith Patrick F.,Pendyala Lakshmi,Greco William R.,Sweeney Kimberly G.,Ford Laurie A.,Wetzler Meir,Baer Maria R.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference43 articles.
1. Akaike H (1979) A Bayesian extension of the minimum AIC procedure of autoregressive model fitting. Biometrika 66:237–242
2. Bass AJ, Gockerman JP, Hammett E, DeCAstro CM, Adams DJ, Rosner GL, Payne N, Davis P, Foster T, Moore JO, Rizzieri DA (2002) Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma. J Clin Oncol 20(13):2995–3000
3. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1976) Proposals for the classification of the acute leukaemias. French–American–British (FAB) co-operative group. Br J Haematol 33(4):451–458
4. Beran M, Kantarjian HM (2000) Topotecan (hycamptin) and topotecan- containing regimens in the treatment of hematologic malignancies. Ann N Y Acad Sci 922:247–259
5. Brooks T, Minderman H, O’Loughlin KL, Pera P, Ojima I, Baer MR, Bernacki RJ (2003) Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol Cancer Ther 2:1195–1205
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献